Patents, Drugs and the Moral High Ground
|Written by Gene Quinn
President & Founder of IPWatchdog, Inc.
Patent Attorney, Reg. No. 44,294
Zies, Widerman & Malek
Blog | Twitter | Facebook | LinkedIn
Posted: April 3, 2014 @ 8:00 am
Meet Gene in Chicago
Join Gene Quinn for a Happy Hour mixer on Tues, Oct. 14, 2014, 5pm to 7pm at The Deck
CLICK HERE to RSVP.
Meet Gene in NJ
Join Gene Quinn for a Happy Hour mixer on Tuesday, Oct. 21, 2014, 5pm to 7pm at The Hyatt Morristown
CLICK HERE to RSVP. Sponsored by Innography.
Recently I had a frustrating morning dealing with a particular anti-patent “do-gooder” who seemingly thinks that everything wrong with the world today is because of the patent system. As is typical with this type of zealot, he intentionally misrepresented what Dr. Kristina Lybecker wrote in her recent article titled Compulsory Licenses Won’t Solve a Healthcare Crisis. Then this ignorant fellow turned on me to say that I supported 9,000 people a day dying in order to preserve patent rights. As you can see, this fellow is not a deep thinker, and not at all capable of honest debate, but isn’t that the case with all those who hate the patent system?
This level of asinine attack would hardly be worthy of my time if it were only the ranting of one particular lunatic, but sadly there are many people who seem to believe that the greater good can be served by stripping pharmaceutical companies of their patent rights and allowing generic drug manufacturers to make the latest drugs in the name of a health crisis. As if preventing a corporation from making money will lead that corporation to simply shrug and start all over again only to have rights stripped away again after billions of dollars of further investment.
The average cost of drug development by a major pharmaceutical company is at least $4 billion per drug, but can be as high as $11 billion per drug. Of course, as is self-evident to anyone capable of critical analysis, no drug company is going to invest billions of dollars to take a drug from laboratory idea to market reality if at the end of the successful trip generic drug manufacturers are allowed to ignore patent rights and immediately start making cheap versions of the patented drug. The generics didn’t have to do any research or engage in the costly and time intensive FDA approval process.
If you know anything about economics, even basic economics, you know that without exclusive rights there is no way for the innovator of the desirable drug to recoup the sunk costs. If you know anything about the pharmaceutical industry you also know that 70% or more of drugs lose money, about 10% of drugs break even, about 10% of drugs make a little more than the break even point, and only about 10% or less of drugs make real money for the pharmaceutical companies. Of course, at the outset no one knows which of the drugs will make the money, so significant time and extraordinary investment is necessary to develop 100% of the drugs. Thus, what seems like a ridiculous price for a particular patented drug is really not just for that drug. The amount made on the successful drug must make up for 90% that are market failures or never make the market, plus provide enough of a profit to make investing billions of dollars a worthwhile endeavor from a risk-reward perspective.
Failure to understand basic economics isn’t the biggest problem of the zealots, or the ignorant patent haters who don’t know better. What really irritates me the most is the fact that these zealots and ignorant haters are among the biggest hypocrites you will ever meet in your life! They are simply not interested in saving lives unless it can be done by abrogating patent rights.
Generally speaking the zealots and haters talk about wanting to abrogate patents on AIDS drugs, or whatever illness is the celebrity cause of the moment. They cry that people are dying at extremely high rates and something has to be done. If you are not with them then you are evil, or as one particular zealot ridiculously accused — you are in favor of people dying. Such a ridiculous, asinine argument is the refuge of someone bereft of intellectual honesty. The full frontal assault with such ridiculous, over the top accusations is done to hide their motivations and make the argument about the motives of those who support patents. Of course, those who support patents know that with patent rights come investment, which leads to research and development, which leads to innovation. But reality doesn’t matter to a zealot.
SAN FRANCISCO Patent Bar Review
LIVE ~ Oct. 29 to Nov. 2, 2014 ~ CLICK HERE to REGISTER
Call 888.296.5973 and mention "IPWatchdog" to save 10%
Truthfully, it is those who are focusing on busting patents and demanding generics be immediately available that are the ones who are morally bankrupt. This is true for several reasons, but it is true primarily and most provably because of their own hypocrisy, which they so carefully try and hide.
Zealots and patent-haters are simply NOT interested in saving lives! If they were they easily could save lives, but they don’t. This is true because the very nature of the patent system that an innovation will be locked up by exclusive rights for only a very limited time. Once the exclusive rights vanish the innovation can be freely used. It is this freedom to use in the very near term future that justifies the patent exclusion in the first place.
There are millions and millions of people dying each year from all kinds of illnesses that are easily preventable using simple technologies and drugs that are off patent. None of the zealots or patent haters seem to want to help these people who were dying, sometimes from horribly painful diseases that are easily preventable in the first place and then easily treated even if acquired. Rather zealots and ignorant patent haters only want to help those dying of a disease that can only realistically be treated by a patented drug. And these hypocrites cry foul? They don’t care about people, or saving lives at all!
Did you know that approximately 1.2 million children will die from diarrheal disease this year alone? That translated into 3,338 deaths a day, 139 every hour and one death ever 26 seconds. Furthermore, 800,000 children under 5 die each year worldwide from diarrhoea, which makes diarrheal diseases the second leading killer of children under 5 worldwide. And I bet you didn’t know that the Center for Disease Control (CDC) says that diarrheal diseases kill more children every day than AIDS, malaria, and measles combined. The CDC says that “[m]ost diarrheal deaths are preventable using simple, low-cost interventions.”
In almost all situations death from diarrheal disease is preventable. Technology dates back to Roman times that could prevent much of these diarrheal diseases, which is caused by unsanitary water. Off-patented drugs could rather easily treat most of the acute illnesses even if they were not prevented. In fact, the off-patent drugs that would treat such diarrheal diseases could be purchased for pennies on the dollar compared to even generic versions of the latest and greatest patented drugs. Yet nothing is being done by the zealots and patent haters to address the terrible problem presented by diarrheal diseases.
Thankfully, there are consortiums within the industry that do care about even those unlucky enough to be stricken with a disease that off-patented drugs will treat. The Infectious Disease Research Institute is an example of a group dedicated to helping transform science into global health solutions while respecting patent rights of those companies that they work with and partner. Of course, few individuals have done more to prevent disease worldwide than Bill and Melinda Gates.
The undeniable, sad truth in all this is that this debate is not about helping people, but rather it’s about helping people only if patented drugs can be vilified and rights stripped.
It sickens me that anti-patent advocates use the AIDS epidemic as a rallying cry against patents, particularly pharmaceutical patents. Aren’t these the same people that vilify the pharmaceutical industry for spending so much time producing lifestyle drugs instead of focusing on life-saving drugs? If we want pharmaceutical companies to continue producing life-saving and life-prolonging drugs, we should not allow for the usurping of patent rights.
The goal of AIDS treatment today is to make it a chronic disease, but how are we going to do that if the pharmaceutical companies cannot make a justifiable return on investment for drugs that are obviously incremental advances towards that ultimate goal?
The sad reality is that we cannot save everybody on the planet who is ill. On some level there is always the need to ration scarce resources, and for the most part there are really only two ways to do this. First, we can do this through a capitalistic approach whereby those who are economically advantaged obtain the resources. Or second, we can attempt to ration resources via some arbitrary approach such as a first in first out system, or perhaps even worse, provide the resources only to those individuals with political power connections. The western world has decided, for the most part, to follow a capitalistic approach, and that is what our patent system chooses. We provide an incentive laden structure for allowing those who come up with unique inventions to be able to reap the rewards associated with bringing useful products to the market. Nowhere is this incentive structure more necessary than in the world of pharmaceuticals, where advancement of drugs is critical necessary to save lives.
But what is the greater good? The question is really quite easy and overwhelmingly in favor of patent rights. When you factor into the equation how early in the process pharmaceutical patents are applied for and then consider the extraordinary length of time it takes to get a drug through the Food and Drug Administration (FDA) approval process, most drug patents provide at best 10 to 14 years of exclusive rights, sometimes less. What that means is that patent rights are provided to protect drugs for about half of a single generation. During that half of a single generation patented drug prices are much higher than you or I would like them to be, there is no doubt about that. But during that half of a single generation the pharmaceutical company needs to make enough money on that drug and all the other failures to make continuing to look for the next drug a financially feasible endeavor. Then after that half of a single generation the once patented drug becomes freely available to the public, including generic manufacturers, for free.
Simply stated, patent rights for half of a single generation in exchange for cheap generic drugs forever thereafter is an outstanding bargain. Only the most blinded zealots and patent haters could ever question the bargain. If you are one of those who do question the bargain notice the next time you feel terrible — like absolute crap. When you go to the pharmacy to fill the prescription given to you by your doctor see how much it costs. It seems to me without fail that the worse I feel the cheaper the drugs prescribed. Why is that? Those drugs are off patent and now each pill costs pennies.
The moral high ground is not occupied by those who demand patent rights be abrogated in order to treat disease. The moral high ground is occupied by the researchers and scientists that dedicate their careers to saving lives, and to the companies and investors that make it possible for those blockbuster life saving drugs to become freely available once a very limited patent life has expired.- - - - - - - - - -
For information on this and related topics please see these archives:
Posted in: Anti-patent Nonsense, Gene Quinn, IP News, IPWatchdog.com Articles, Patents, Pharmaceutical
About the Author
Gene Quinn is a Patent Attorney and the founder of the popular blog IPWatchdog.com, which has for three of the last four years (i.e., 2010, 2012 and 2103) been recognized as the top intellectual property blog by the American Bar Association. He is also a principal lecturer in the PLI Patent Bar Review Course. As an electrical engineer with a computer engineering focus his specialty is electronic and computer devices, Internet applications, software and business methods.